Search

Displaying results 8391 - 8400 of 8415 in total
  1. Drug

    Bafilomycin A1

    go.drugbank.com/drugs/DB06733
    Experimental

    This is a useful tool as it can prevent the re-acidification of synaptic vesicles once they have undergone exocytosis.

  2. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    It is also investigating use of the compound for neurodegenerative disorders, such as Huntington’s disease and Alzheimer’s disease.

  3. Drug

    FINLAY-FR-1

    go.drugbank.com/drugs/DB16524
    Experimental

    FINLAY-FR-1, also known as Soberana 01, is a vaccine candidate for COVID-19 that is being led developmentally by the Finlay Vaccine Institute[L31373].

  4. Drug

    Diminazene

    go.drugbank.com/drugs/DB03608
    Experimental

    Diminazene, also known as Diminazine, 4,4'-(Diazoamino)benzamidine, 4,4'-(1-triazene-1,3-diyl)bis-benzenecarboximidamide, diminazine aceturate, or Diminazene aceturate, is a trypanocidal agent.

  5. Drug

    MYR-101

    go.drugbank.com/drugs/DB17075
    Investigational

    [L43567] The FDA has granted MYR-101 Fast Track, Rare Pediatric Disease (RPD), and Orphan Drug designations for the treatment of patients with Canavan disease.[L43572]

  6. Drug

    Distigmine

    go.drugbank.com/drugs/DB13694
    Investigational

    Distigmine is available in several countries as a treatment of underactive detrusor and voiding dysfunction in the urinary tract where the active ingredient is distigmine bromide.

  7. Drug

    G17DT Immunogen

    go.drugbank.com/drugs/DB04914
    Investigational

    It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.

  8. Drug

    DDP733

    go.drugbank.com/drugs/DB05049
    Investigational

    DDP733 is an oral prokinetic drug which Dynogen is developing as a treatment for both Irritable Bowel Syndrome with constipation (IBS-c) and nocturnal gastroesophageal reflux disease (NGERD).

  9. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

  10. Drug

    DTS-201

    go.drugbank.com/drugs/DB06071
    Experimental

    solid tumors, including tumors sensitive to doxorubicin and potentially other tumors which are not currently treated with doxorubicin but which express high levels of CD-10* or TOP** peptidases, such as